Selective Termination of protein Synthesis Platform

Initial Therapeutics is pioneering a novel approach to disease intervention through its proprietary Selective Termination of Protein Synthesis (STOPS) platform. This innovative technology targets the ribosome, the cellular machinery responsible for protein synthesis, to selectively stall the formation of pathogenic proteins associated with various diseases. By focusing on known high-value targets that have traditionally been deemed "undruggable," Initial Therapeutics aims to intercept the translation of these proteins at an early stage, thereby preventing the onset of disease processes. This method represents a significant shift from conventional drug discovery, which typically involves targeting fully formed proteins.

The STOPS platform offers several advantages over traditional therapeutic strategies, particularly in its ability to modulate the activity of disease-causing proteins without the need for prior structural characterization of the mature protein. By intervening at the nascent stage of protein formation, Initial Therapeutics seeks to avoid complications such as protein aggregation and other molecular pathologies that are challenging to reverse. This early intervention strategy not only enhances the potential for therapeutic benefit but also positions Initial Therapeutics at the forefront of addressing some of the most challenging targets in cancer and other life-threatening illnesses.

United States

Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages.

Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.


Initial Therapeutics

Company Details